Patient Portal

David Michael Holtzman, MD

Andrew B. and Gretchen P. Jones Professor of Neurology
Charlotte and Paul Hagemann Professor of Neurology
Chairman, Department of Neurology
Professor, Molecular Biology and Pharmacology
Neurologist-in-Chief, Barnes-Jewish Hospital

Specialty Areas

Neurology - Adult
Memory Disorders and Diagnosis
Alzheimer's Disease
Dementia

Board Certifications

Neurology

Hospital Affiliations

Barnes-Jewish Hospital

Areas of Clinical Interest

Neurology, molecular biology, pharmacology, nervous system, Alzheimer's disease, memory, brain research, cerebral blood flow, metabolism, neuroscience, lipid research, neuron, mental retardation, Down's syndrome, neonatal hypoxic-ischemia, brain disorders, spinal fluid.

  • Location(s)
  • Education
  • Publication & Research
  • Financial Disclosures

Location(s)

Location(s)

Center for Advanced Medicine
Memory Diagnostic Center

4921 Parkview Place
St. Louis, MO 63110

Suite: C
Floor: 6
Office Phone: (314) 286-1967
Fax: (314) 286-1985
Email: holtzman@neuro.wustl.edu

Education

Education

Residency: Neurology, University of California, San Francisco, California 1989
Medical Degree: Northwestern University, Chicago, Illinois 1985
BS: Science in Medical Education, Northwestern University, Chicago, Illinois 1983

Publication & Research

Publication & Research

Lack of hepatic apoE does not influence early Aβ deposition: observations from a new APOE knock-in model.
Huynh TV, Wang C, Tran AC, Tabor GT, Mahan TE, Francis CM, Finn MB, Spellman R, Manis M, Tanzi RE, Ulrich JD, Holtzman DM
Mol Neurodegener. 2019 Oct 17; 14(1)37. doi: 10.1186/s13024-019-0337-1.

PMID:
    31623648
    [PubMed - in process]
Related citations


Microglia drive APOE-dependent neurodegeneration in a tauopathy mouse model.
Shi Y, Manis M, Long J, Wang K, Sullivan PM, Remolina Serrano J, Hoyle R, Holtzman DM
J Exp Med. 2019 Oct 10; pii: jem.20190980. doi: 10.1084/jem.20190980.

PMID:
    31601677
    [PubMed - as supplied by publisher]
Related citations


Alzheimer Disease: An Update on Pathobiology and Treatment Strategies.
Long JM, Holtzman DM
Cell. 2019 Oct 3; 179(2)312-339. doi: 10.1016/j.cell.2019.09.001.

PMID:
    31564456
    [PubMed - in process]
Related citations


The microbiome: A target for Alzheimer disease?
Seo DO, Boros BD, Holtzman DM
Cell Res. 2019 Oct; 29(10)779-780. doi: 10.1038/s41422-019-0227-7.

PMID:
    31488883
    [PubMed - in process]
Related citations


Bidirectional relationship between sleep and Alzheimer's disease: role of amyloid, tau, and other factors.
Wang C, Holtzman DM
Neuropsychopharmacology. 2019 Aug 13; doi: 10.1038/s41386-019-0478-5.

PMID:
    31408876
    [PubMed - as supplied by publisher]
Related citations


Translocator protein in late stage Alzheimer's disease and Dementia with Lewy bodies brains.
Xu J, Sun J, Perrin RJ, Mach RH, Bales KR, Morris JC, Benzinger TLS, Holtzman DM
Ann Clin Transl Neurol. 2019 Aug; 6(8)1423-1434. doi: 10.1002/acn3.50837.

PMID:
    31402620
    [PubMed - in process]
Related citations


A single-nuclei RNA sequencing study of Mendelian and sporadic AD in the human brain.
Del-Aguila JL, Li Z, Dube U, Mihindukulasuriya KA, Budde JP, Fernandez MV, Ibanez L, Bradley J, Wang F, Bergmann K, Davenport R, Morris JC, Holtzman DM, Perrin RJ, Benitez BA, Dougherty J, Cruchaga C, Harari O
Alzheimers Res Ther. 2019 Aug 9; 11(1)71. doi: 10.1186/s13195-019-0524-x.

PMID:
    31399126
    [PubMed - in process]
Related citations


High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis.
Schindler SE, Bollinger JG, Ovod V, Mawuenyega KG, Li Y, Gordon BA, Holtzman DM, Morris JC, Benzinger TLS, Xiong C, Fagan AM, Bateman RJ
Neurology. 2019 Aug 1; pii: 10.1212/WNL.0000000000008081. doi: 10.1212/WNL.0000000000008081.

PMID:
    31371569
    [PubMed - as supplied by publisher]
Related citations


TREM2 function impedes tau seeding in neuritic plaques.
Leyns CEG, Gratuze M, Narasimhan S, Jain N, Koscal LJ, Jiang H, Manis M, Colonna M, Lee VMY, Ulrich JD, Holtzman DM
Nat Neurosci. 2019 Aug; 22(8)1217-1222. doi: 10.1038/s41593-019-0433-0.

PMID:
    31235932
    [PubMed - in process]
Related citations


Emerging cerebrospinal fluid biomarkers in autosomal dominant Alzheimer's disease.
Schindler SE, Li Y, Todd KW, Herries EM, Henson RL, Gray JD, Wang G, Graham DL, Shaw LM, Trojanowski JQ, Hassenstab JJ, Benzinger TLS, Cruchaga C, Jucker M, Levin J, Chhatwal JP, Noble JM, Ringman JM, Graff-Radford NR, Holtzman DM, Ladenson JH, Morris JC, Bateman RJ, Xiong C, Fagan AM, Dominantly Inherited Alzheimer Network.
Alzheimers Dement. 2019 May; 15(5)655-665. doi: 10.1016/j.jalz.2018.12.019.

PMID:
    30846386
    [PubMed - in process]
Related citations


Dural lymphatics regulate clearance of extracellular tau from the CNS.
Patel TK, Habimana-Griffin L, Gao X, Xu B, Achilefu S, Alitalo K, McKee CA, Sheehan PW, Musiek ES, Xiong C, Coble D, Holtzman DM
Mol Neurodegener. 2019 Feb 27; 14(1)11. doi: 10.1186/s13024-019-0312-x.

PMID:
    30813965
    [PubMed - indexed for MEDLINE]
Related citations


Tau PET in autosomal dominant Alzheimer's disease: relationship with cognition, dementia and other biomarkers.
Gordon BA, Blazey TM, Christensen J, Dincer A, Flores S, Keefe S, Chen C, Su Y, McDade EM, Wang G, Li Y, Hassenstab J, Aschenbrenner A, Hornbeck R, Jack CR, Ances BM, Berman SB, Brosch JR, Galasko D, Gauthier S, Lah JJ, Masellis M, van Dyck CH, Mintun MA, Klein G, Ristic S, Cairns NJ, Marcus DS, Xiong C, Holtzman DM, Raichle ME, Morris JC, Bateman RJ, Benzinger TLS
Brain. 2019 Apr 1; 142(4)1063-1076. doi: 10.1093/brain/awz019.

PMID:
    30753379
    [PubMed - in process]
Related citations


Dr. Jekyll and Mr. Hyde: ApoE explains opposing effects of neuronal LRP1.
Strickland MR, Holtzman DM
J Clin Invest. 2019 Mar 1; 129(3)969-971. doi: 10.1172/JCI127578.

PMID:
    30741722
    [PubMed - in process]
Related citations


Multi-Modal Home Sleep Monitoring in Older Adults.
Toedebusch CD, McLeland JS, Schaibley CM, Banks IR, Boyd J, Morris JC, Holtzman DM, Lucey BP
J Vis Exp. 2019 Jan 26; (143)doi: 10.3791/58823.

PMID:
    30741255
    [PubMed - in process]
Related citations


Reply to "obstructive sleep apnea treatment and amyloid-β in cerebrospinal fluid".
Ju YS, Holtzman DM
Ann Neurol. 2019 Mar; 85(3)460-461. doi: 10.1002/ana.25424.

PMID:
    30706528
    [PubMed - in process]
Related citations


The sleep-wake cycle regulates brain interstitial fluid tau in mice and CSF tau in humans.
Holth JK, Fritschi SK, Wang C, Pedersen NP, Cirrito JR, Mahan TE, Finn MB, Manis M, Geerling JC, Fuller PM, Lucey BP, Holtzman DM
Science. 2019 Feb 22; 363(6429)880-884. doi: 10.1126/science.aav2546.

PMID:
    30679382
    [PubMed - indexed for MEDLINE]
Related citations


"Alzheimer's disease" is neither "Alzheimer's clinical syndrome" nor "dementia".
Jagust W, Jack CR Jr, Bennett DA, Blennow K, Haeberlein SB, Holtzman DM, Jessen F, Karlawish J, Liu E, Molinuevo JL, Montine T, Phelps C, Rankin KP, Rowe CC, Scheltens P, Siemers E, Sperling R
Alzheimers Dement. 2019 Jan; 15(1)153-157. doi: 10.1016/j.jalz.2018.11.002.

PMID:
    30642435
    [PubMed - indexed for MEDLINE]
Related citations


Reduced non-rapid eye movement sleep is associated with tau pathology in early Alzheimer's disease.
Lucey BP, McCullough A, Landsness EC, Toedebusch CD, McLeland JS, Zaza AM, Fagan AM, McCue L, Xiong C, Morris JC, Benzinger TLS, Holtzman DM
Sci Transl Med. 2019 Jan 9; 11(474)pii: eaau6550. doi: 10.1126/scitranslmed.aau6550.

PMID:
    30626715
    [PubMed - in process]
Related citations


Loss of TREM2 function increases amyloid seeding but reduces plaque-associated ApoE.
Parhizkar S, Arzberger T, Brendel M, Kleinberger G, Deussing M, Focke C, Nuscher B, Xiong M, Ghasemigharagoz A, Katzmarski N, Krasemann S, Lichtenthaler SF, Müller SA, Colombo A, Monasor LS, Tahirovic S, Herms J, Willem M, Pettkus N, Butovsky O, Bartenstein P, Edbauer D, Rominger A, Ertürk A, Grathwohl SA, Neher JJ, Holtzman DM, Meyer-Luehmann M, Haass C
Nat Neurosci. 2019 Feb; 22(2)191-204. doi: 10.1038/s41593-018-0296-9.

PMID:
    30617257
    [PubMed - indexed for MEDLINE]
Related citations


Assessment of Racial Disparities in Biomarkers for Alzheimer Disease.
Morris JC, Schindler SE, McCue LM, Moulder KL, Benzinger TLS, Cruchaga C, Fagan AM, Grant E, Gordon BA, Holtzman DM, Xiong C
JAMA Neurol. 2019 Mar 1; 76(3)264-273. doi: 10.1001/jamaneurol.2018.4249.

PMID:
    30615028
    [PubMed - in process]
Related citations

Financial Disclosures

Financial Disclosures

Disclosure of Financial Interests with Industry

Washington University and its physicians and health professionals are committed to ensuring integrity and objectivity in medical decision-making. Some of our physicians and health professionals work collaboratively with pharmaceutical, medical device or other medical care related companies to develop innovative ideas and products that can improve health care delivery and clinical outcomes for patients. In some instances, our physicians and health professionals have an ownership or potential ownership interest in a commercial company; and/or are paid by a commercial company to provide advice on product design or to speak about the use of medications, devices, equipment or procedures. These payments may include: a) compensation for consulting and speaking engagements, b) equity, and/or c) royalties for products invented by our faculty. Any payments to Washington University physicians or health professionals must be based on tangible services and may not exceed fair market value for their work. In addition to disclosure on this website, physicians and health professionals earning more than $10,000 per year must disclose their corporate financial relationship in writing to patients when prescribing or using that company's products.

This physician reported the following financial interests during calendar year 2018:

Company Name: C2N Diagnostics

Royalties: > $250,000

Equity: Yes

Consulting/Advisory Board: $20,000 - $39,999

Speaker Fees:

Reporting Date: May 01, 2019


Company Name: Denali

Royalties: $1 - $9,999

Equity: No

Consulting/Advisory Board: $10,000 - $19,999

Speaker Fees:

Reporting Date: May 01, 2019


Company Name: Proclara

Royalties:

Equity: No

Consulting/Advisory Board: $20,000 - $39,999

Speaker Fees:

Reporting Date: May 01, 2019

Areas of Research Interest

Underlying mechanisms that lead to Alzheimer's disease.